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Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal 
chromosomal translocation between chromosomes 9 and 22 [t(9;22)], producing the 
Bcr-Abl oncogene. Tyrosine kinase inhibitors (TKIs) represent the standard of care for 
CML patients and exert a dual mode of action: direct oncokinase inhibition and res-
toration of effector-mediated immune surveillance, which is rendered dysfunctional in 
CML patients at diagnosis, prior to TKI therapy. TKIs such as imatinib, and more potent 
second-generation nilotinib and dasatinib induce a high rate of deep molecular response 
(DMR, BCR-ABL1 ≤ 0.01%) in CML patients. As a result, the more recent goal of therapy 
in CML treatment is to induce a durable DMR as a prelude to successful treatment-free 
remission (TFR), which occurs in approximately half of all CML patients who cease TKI 
therapy. The lack of overt relapse in such patients has been attributed to immunological 
control of CML. In this review, we discuss an immunological timeline to successful TFR, 
focusing on the immunology of CML during TKI treatment; an initial period of immune 
suppression, limiting antitumor immune effector responses in newly diagnosed CML 
patients, linked to an expansion of immature myeloid-derived suppressor cells and 
regulatory T cells and aberrant expression of immune checkpoint signaling pathways, 
including programmed death-1/programmed death ligand-1. Commencement of TKI 
treatment is associated with immune system re-activation and restoration of effector-me-
diated [natural killer (NK) cell and T cell] immune surveillance in CML patients, albeit with 
differing frequencies in concert with differing levels of molecular response achieved on 
TKI. DMR is associated with maximal restoration of immune recovery in CML patients 
on TKI. Current data suggest a net balance between both the effector and suppressor 
arms of the immune system, at a minimum involving mature, cytotoxic CD56dim NK cells 
may be important in mediating TFR success. However, a major goal remains in CML to 
identify the most effective pathways to target to maximize an advantageous immune 
response and promote TFR success.
Keywords: immunology, chronic myeloid leukemia, treatment-free remission, immune surveillance, deep 
molecular response
iNTRODUCTiON
Chronic myeloid leukemia (CML) is a hematological cancer characterized by the presence of the 
BCR-ABL1 oncogene, which is the product of a reciprocal translocation between chromosomes 9 
and 22 [t(9;22)], in a hematopoietic stem cell. The resultant constitutively active tyrosine kinase, 
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Bcr-Abl, mediates phosphorylation and activation of downstream 
signaling pathways, causing altered cell adhesion, inhibition of 
apoptosis, differentiation arrest, and proteasomal degradation of 
key proteins, which lead to the phenotype of the disease (1). CML 
is considered to be one of the cancers most sensitive to immu-
nological manipulation (2). Tyrosine kinase inhibitors (TKIs) 
imatinib, nilotinib, and dasatinib are used as first-line treatment 
in CML. These small molecule inhibitors block the adenosine 
triphosphate-binding site of the Bcr-Abl tyrosine kinase and pre-
vent phosphorylation of downstream effector proteins. Clinical 
response to treatment is assessed initially by monitoring the 
reduction of the peripheral white blood cell count, and subse-
quently by measurement of BCR-ABL1 transcript levels against 
a control gene (3). An optimal response following initiation of 
TKI treatment is a major goal, as this confers improved patient 
survival. Clinical guidelines on optimal molecular responses 
refer to achievement of target BCR-ABL1 levels [e.g., ≤0.1%, 
major molecular response (MMR)] at specific timepoints (4). The 
more recent goal in CML treatment is to induce a durable deep 
molecular response (DMR; BCR-ABL1 ≤  0.01%) as a prelude 
to successful treatment-free remission (TFR), which occurs in 
approximately half of all CML patients who cease TKI therapy 
(5, 6). The lack of overt relapse in such patients has been attrib-
uted to immunological control of CML (7), although its precise 
mechanisms are as yet unclear.
Suppression of the innate and adaptive immune system, linked 
to an accumulation of immature myeloid cells (myeloid-derived 
suppressor cells, MDSCs), predominates during pathological 
conditions such as cancer, and leads to inhibition of the host–
antitumor immunity (8). MDSC expansion in the blood and 
bone marrow at the time of diagnosis has been shown in patients 
with multiple myeloma (9), chronic lymphocytic leukemia (10), 
and acute myeloid leukemia (11). In CML, increased levels of 
MDSC, which originate from the malignant BCR-ABL1 clone, 
are also observed, and these MDSC subsequently reduce follow-
ing highly efficacious TKI therapy (12, 13). MDSCs promote the 
recruitment and expansion of other suppressor cells (regulatory 
T cells, Treg), leading to impaired innate effector natural killer 
(NK) cells and inhibition of T cell proliferation and activation, 
further downregulating antitumor immune surveillance that 
subsequently influence leukemia development and progression 
(14). In support, quantitative and functional defects of NK cells 
and diminished cytotoxic T lymphocyte (CTL) function have also 
been described in chronic phase (CP) CML patients at diagnosis 
(12, 15–17). Thus, the changing ratio between resident immune 
effector and immune suppressor cells in untreated CML and 
other hematological cancers, limits the patient’s immune status 
such that a predominantly immune inhibitory leukemic milieu 
is present, accounting for a diminished anti-leukemic effector 
immune response to control leukemia progression and/or relapse. 
Very recently, an increased proportion of mature, adaptive-like 
CD56dim NK  cells have been observed in CML patients who 
successfully discontinued imatinib (18). Other immunologic 
mediators such as plasmacytoid dendritic cells (pDCs), which 
may serve as promising prognostic factors for successful TFR, 
are also currently under investigation (19). TKIs also exert 
significant off-target multikinase inhibitory effects, albeit with 
differing potencies. Cumulative data suggest that TKIs exhibit a 
dual mode of action; direct oncokinase inhibition interspersed 
with concomitant immunomodulatory effects, particularly 
against key suppressor MDSC and Treg populations, conferring 
immune system re-activation and restoring effector-mediated 
immune surveillance (2, 13, 20–24). In this review, we discuss 
an immunological timeline to successful TFR in CML; an initial 
period of immune dysfunction in newly diagnosed CML patients, 
followed by restoration of immune effector responses and release 
of immune suppressors, albeit with differing frequencies in 
concert with differing levels of molecular response achieved on 
TKI. Optimum restoration of endogenous immune surveillance 
mechanisms may promote sustained TFR following TKI discon-
tinuation attempt.
iMMUNe DYSFUNCTiON iN NewLY 
DiAGNOSeD CML PATieNTS
The majority (~90%) of CML patients are diagnosed while in 
CP, characterized by an expansion of circulating myeloid cells, 
which are mainly mature, and maintained by a small subset of 
disease initiating leukemic stem cells (LSCs) (25). Persistent 
immune dysfunction in CML patients at the time of diagnosis, 
prior to the start of any therapy is well documented, precluding 
the development of adequate anti-leukemia immune responses 
and promoting disease progression in the absence of highly effi-
cacious TKI therapy. An essential role of the immune system, in 
particular that of innate and adaptive immune cells (i.e., NK cells, 
CD8+/CD4+ T cells), effector molecules, and endogenous signal-
ing pathways, is to confer host protection against cancer (26). 
However, many tumors facilitate their self preservation and 
progression by the recruitment of immunosuppressive cells, 
release of inhibitory factors including immunosuppressive and 
inflammatory cytokines and upregulation of immune checkpoint 
pathways, in particular cytotoxic T-lymphocyte-associated 
protein 4 and programmed death-1 (PD-1) pathways (27, 28). 
The ligand for PD-1, programmed death ligand-1 (PD-L1), 
induces a coinhibitory signal in activated T cells and promotes 
T cell apoptosis, anergy, and functional exhaustion (29). Further 
research into better understanding this altered immune balance 
in CML patients at diagnosis is essential for the development of 
new therapeutic methods, aiming to augment antitumor immune 
activity and enhance TFR success rates following TKI cessation.
eFFeCTOR CeLLS OF THe iMMUNe 
SYSTeM iN CML PATieNTS AT DiAGNOSiS
The main antitumor effector cells of the immune system, NK cells, 
dendritic cells (DCs), and CTLs (30), play a direct role in host con-
trol of hematological malignancies, including CML. Antibody-
secreting effector B cells, also called plasma cells also defend the 
body in an immune response, with distinct B cell subsets mediat-
ing different types of antibody responses (31). de Lavallade et al. 
(32) have previously reported loss of memory B cell subsets in 
CML patients at diagnosis; however, the clinical impact remains 
unclear, with no patients showing recurrent infections despite 
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the B  cell deficiency. In support, we have performed extensive 
characterization of major B  cell subsets including transitional, 
naïve, non-switched memory, class-switched memory, plasmab-
lasts, and plasma cells and observed non-switched memory B cell 
expression was decreased in CML patients at diagnosis compared 
to normal healthy donor samples (12).
Natural killer cells are lymphocytes and a critical component 
of the innate immune system, providing a front line defense 
against tumor cells. NK  cells exert potent cellular cytotoxicity 
against malignant cells (CD56dim NK  cell subset) and pro-
duce immunoregulatory cytokines and chemokines, such as 
interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α), 
supporting the development of adaptive immunity (CD56bright 
NK  cell subset). In contrast to T  cells that require interaction 
with professional antigen-presenting cells, such as mature DCs 
for activation, NK cells utilize a diverse array of inhibitory and 
activating receptors for target cell recognition and lysis with no 
requirement for prior antigen stimulation or clonal expansion 
(33). NK cells are dysfunctional in CP CML patients at diagnosis 
and NK cell numbers among lymphocytes are reduced, worsen-
ing with disease progression to advanced and blast crisis phase 
CML (15, 16, 34). The activating C-type lectin receptor NKG2D 
stimulates the cytotoxicity of NK cells following recognition of 
the stress-induced ligand major histocompatibility complex class 
I chain-related A (MICA). BCR-ABL1 promotes DC-mediated 
NK cell activation by increasing the expression of NKG2D ligands 
including MICA (35). MICA releases soluble proteins produced 
on the surface of tumor cells, inducing negative modulation of 
NKG2D and facilitating tumor cell escape from NK cell killing 
(36–38). Reduced NKG2D-activating receptor expression has 
been previously identified in CML patients at diagnosis, pro-
moting leukemic cell survival (36). Very recently, we identified 
reduced expression of the NKG2 family of C-type lectin receptors 
(CD94/NKG2A, CD94/NKG2C, and NKG2D) in CML patients 
at diagnosis (12). Similarly, the natural cytotoxicity receptors 
NKp30 and NKp46, the latter characterized as the major trigger-
ing receptor involved in NK cell cytotoxicity (39) and the killer 
immunoglobulin-like receptors (KIRs) KIR2DL2/DL3/DS2 were 
downregulated in CML patients at diagnosis compared to healthy 
donors. Downregulation of NKp30 and NKp46 has been reported 
previously in acute myeloid leukemia and chronic lymphocytic 
leukemia and shown to correlate with decreased NK cell cyto-
toxicity (40–42).
Dendritic cells are the most potent antigen-presenting cells in 
promoting activation of naïve T cells and play a critical role in the 
initiation and regulation of the immune response (43). DCs take 
up, process, and present antigens on major histocompatibility 
(MHC) class I and II molecules on the cell surface, to T  cells, 
thus initiating antigen-specific immune responses and/or immu-
nological tolerance (44). In normal peripheral blood, myeloid 
and pDC subsets are typically identified in the immature state 
in low numbers, in contrast, quantitative and functional defects 
including inefficient antigen presentation have been reported in 
DC subsets from CML patients (45–48).
Leukemia-associated antigen (LAA)-specific CTLs have 
been detected in the peripheral blood of CP CML patients, 
including CTLs specific for Bcr-abl and selectively expressed 
or overexpressed LAAs such as proteinase-3 (PR3) and Wilms’ 
tumor antigen 1 (WT1), and may be involved in the immunologi-
cal control of CML (49–51). However, studies have shown T cells 
from untreated patients with CML are functionally impaired, 
displaying decreased TCRζ-chain expression, limited cytotoxic 
activity, and they do not produce immunoregulatory cytokines 
IFN-γ or TNF-α (52–54). TCRζ-chain expression is critical for 
normal T cell function, including proliferation and IFN-γ produc-
tion (55). Molldrem et al. (56) suggest a novel escape mechanism 
from tumor immunity by leukemia-induced selective deletion of 
high avidity effector CTLs that have the greatest potency against 
CML.
CD62L downregulation may impair effector CTL immune 
responses in CML patients at diagnosis and abrogate anti-
leukemic immune control, as CD62L is critical in controlling 
the traffic of T cells to secondary lymphoid tissues and priming 
by antigen-presenting cells. Sopper et  al. (57) have reported 
decreased CD62L surface expression on T cells in CML patients 
at diagnosis. Another mechanism of impaired immune response 
in CML may involve aberrant PD-1/PD-L1 signaling on effector 
cells, and immunosuppressive Treg, which also express PD-1. 
PD-1 is temporarily expressed on activated immune effector cells 
under normal physiological conditions; however, constitutive 
expression results in diminished effector T  cell function, and 
expansion of Treg with enhanced suppressor function, the latter 
playing a critical role in maintenance of the immunosuppressive 
tumor milieu (17, 58, 59). Mumprecht et al. (60) have previously 
reported PD-1 is upregulated on CML-specific CTLs and also on 
CTLs specific for unrelated antigens. Higher PD-1 expression 
in CTLs is related to inhibition of the effector phase of T  cell 
responses and reduced T  cell-mediated antitumor immunity 
(28). In addition, we have shown increased PD-1 expression on 
CD4+ and CD8+ T cells in CML patients at diagnosis, suggesting 
the presence of a broadly compromised immune system in CML 
patients at diagnosis (12).
SUPPReSSOR CeLLS OF THe iMMUNe 
SYSTeM iN CML PATieNTS AT DiAGNOSiS
Myeloid-derived suppressor cells are a heterogeneous popula-
tion of immature granulocytic and monocytic cells with potent 
immune suppressive functions and therefore represent one of the 
main suppressor cell populations within the immune system (61). 
MDSCs expand during cancer, inflammation, and infection and 
are characterized by the ability to suppress the cytotoxic func-
tion of T cells, including leukemia-specific CTLs, and NK cells 
(62). Cancer-derived inflammation drives the expansion and 
suppressive activity of MDSC, this is facilitated by multiple pro-
inflammatory factors including GM-CSF and VEGF, produced 
within the immunosuppressive tumor microenvironment 
(63, 64). MDSC suppressive activity is mediated via a number of 
mechanisms, including increased production of reactive oxygen 
and nitrogen species and upregulation of arginase-1, the latter 
culminating in local depletion of arginine, an essential amino 
acid for T  cell function (62, 65, 66) and depletion of cysteine, 
required by antigen-presenting cells including DCs, for effec-
tive T  cell activation (67). Arginase-1 has also been shown to 
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inhibit NK  cell proliferation and secretion of IFN-γ (68) and 
MDSC induce anergy of NK  cells through membrane-bound 
TGF-β1 (69). CML patients express high levels of monocytic and 
granulocytic MDSC at diagnosis compared to healthy donors 
(12, 13, 21), and these MDSC express BCR-ABL1 and are part of 
the leukemia clone (13). In addition, CML serum leads to anergy 
of T cells, probably by increased arginase-1 expression (13) and 
coincubation of isolated monocytic and granulocytic MDSC of 
CML patients at diagnosis and autologous CFSE-labeled T cells 
has been shown to inhibit T cell proliferation, whereas control 
healthy donor MDSC displayed no suppressive activity (70).
Myeloid-derived suppressor cells also mediate the recruitment 
and expansion of immunosuppressive Treg, a specialized type of 
CD4+ T cell expressing the transcription factor forkhead box P3 
(FoxP3), that can compromise the function of antitumor effector 
CD4+/CD8+ T cells and antigen-presenting cell activity to facilitate 
tumor cell immune evasion (62, 71–77). Zahran et al. (78) have 
reported the percentages of Tregs are significantly increased in 
newly diagnosed CML patients compared to controls, with lower 
Treg numbers in CP CML patients compared to accelerated and 
blast phases. In support, Bachy et al. (79) have shown that Treg 
are significantly increased in CML patients with intermediate or 
high-risk Sokal scores compared to low-risk patients. Thus, in a 
setting of high leukemic cell load in CP CML patients at diagnosis, 
CML cells can evade host immune surveillance by activation of 
the immune checkpoint receptor PD-1 and via PD-L1 upregula-
tion, this signaling pathway influences immune suppression and 
disease progression, further supported by the recruitment of 
immunosuppressive MDSC and Treg cell populations (28).
iMMUNOGeNiCiTY OF CML
The constitutively active Bcr-Abl kinase, while only weakly 
immunogenic in itself, leads to the upregulation of multiple genes, 
which may result in the expression of LAAs critical for priming 
of a protective antitumor CTL response against CML cells (80). 
The cure of CML following allogeneic hematopoietic stem cell 
transplantation (SCT) is attributed to the immunological graft-
versus-leukemia effect, which is mediated by donor-derived 
T  cells and NK  cells, targeting alloantigens, primarily minor 
histocompatibility antigens (mHAgs) (81) and likely also LAAs 
(50, 82–84) and considered to play a critical role in disease 
eradication. Donor lymphocyte infusion after SCT provided the 
first direct evidence of the graft-versus-leukemia effect, in which, 
CTLs with mHAg specificity could salvage disease relapse (85, 
86). The presence of LAA-specific CTLs directed against PR3 was 
associated with clinical responses to SCT (50, 84). In earlier func-
tional studies, LAA-specific CTL responses to WT1 and PR3 were 
identified in CML patients and healthy donors, albeit at a lower 
frequency in the latter, and shown to expand in the recipient after 
transplantation, contributing to remission (83). Direct evidence 
of high in vivo antigen-specific immunogenicity against the LAA 
BMI-1 has also been found in the setting of SCT in CML (82).
Specific immunotherapies for CML patients targeting LAAs in 
combination with imatinib or other TKIs may exert a synergistic 
effect, inducing DMR in a high percentage of patients, while hav-
ing the potential to overcome disease resistance by eliminating 
the quiescent CML stem cell subpopulation and enhancing spe-
cific immune responses against CML (80). In addition to BMI-1, 
WT1, and PR3, several other LAAs have been identified in 
CML patients such as RHAMM/CD186 and PRAME (82, 87–89) 
and thus represent candidate antigens for specific immunothera-
pies, with efficacy demonstrated in vaccination, including DC 
vaccination (90–93) and more recently, T  cell receptor mimic 
antibodies (94, 95). Significant differences exist in the expression 
of LAAs relevant to CML disease progression and response, and 
CD34+ progenitor maturation in CML (81, 96), suggesting the 
importance of combining several antigens in future immuno-
therapeutic strategies. For effective activation of effector CTL 
responses, MHC molecules and costimulatory proteins are 
necessary, aberrant expression of these molecules can lead to 
immune evasion of cancer (26). Progenitor cells of CML patients 
(CD34+CD38+, CD34+CD38−, CD34+CD38−CD90+) actively 
evade host immune surveillance through cytokine-mediated 
downregulation of MHC-II and its master regulator class II 
transactivator (CIITA), a transcription factor that functions as a 
molecular switch for MHC-II gene regulation, and may explain 
why CML stem cells persist despite lifelong TKI treatment (97). 
CIITA plays a central role in MHC-II antigen presentation to 
effector CD4+ T cells, and thus in the stimulation of the adap-
tive immune response. Treatment of cells with the receptor TKI 
ruxolitinib (and to a lesser extent IFN-γ) enhanced the expression 
of MHC-II on CML stem/progenitor cells and was associated 
with an increase in CML cell immunogenicity (enhanced CD4+ 
T cell proliferation) in a JAK-dependent manner (97, 98). In sup-
port, clinical studies investigating the combination regimen of 
ruxolitinib and TKIs imatinib, dasatinib, and nilotinib in control 
of CML (NCT02253277, NCT01751425, and NCT01702064) 
are currently ongoing. The development of immunotherapeutic 
strategies to enhance MHC-II expression on CML stem/progeni-
tor cells may facilitate their elimination by host immune effectors 
and result in greater rates of success in TFR discontinuation 
studies.
THe iMMUNe SYSTeM iS NOT 
PeRMANeNTLY COMPROMiSeD iN CML
The introduction of TKIs has dramatically improved disease 
outcome in patients with CML and has replaced interferon-alpha 
(IFN-α) and SCT as frontline therapy (99). The therapeutic 
efficacy of IFN is mediated at least in part by immunological 
mechanisms and by the ability to cycle quiescent LSCs, responsi-
ble for disease initiation (100). The mechanism of action of TKIs, 
while remarkably different to that of IFN, is also accompanied 
by immune system re-activation, suggesting the immune system 
is not permanently compromised in CML (101, 102). A cur-
rent limitation of immunological studies in CML is the limited 
investigation of immune responses longitudinally in the same 
patient cohort over time, for example, studies of patient samples 
at diagnosis, on TKI and following achievement of DMR, which 
may be achieved very quickly or many years later. This is further 
compounded by a lack of studies directly comparing the level of 
immune system re-activation and/or the timing of re-activation 
achieved with first-generation TKI imatinib compared to more 
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potent second-generation TKIs nilotinib and dasatinib, the 
latter known to possess strong inhibitory activity with broader 
specificity against multiple other kinases including Src, Tec, and 
Syk family kinases, many of these being involved in innate and 
adaptive immune responses (103–105). Bosutinib and ponatinib 
are both indicated for second- or later-line treatment of CML, no 
studies to date appear to have explored their immunomodulatory 
effect on immune cell populations. We have reported maximal 
restoration of immune recovery in CML patients on TKI occurs 
only following achievement of MR4.5 (BCR-ABL1 ≤0.0032%), as 
demonstrated by increased effector NK cell number and function 
and T cell immune responses, reduced numbers of PD-1+ CD4+/
CD8+ T cells and monocytic MDSC (12). This suggests there may 
be a staged recovery of some immune responses in CML patients 
on TKI, which may be linked to depth of molecular response 
achieved; however, the specific causal relationship between both 
phenomena remains to be fully elucidated.
THe iMMUNOMODULATORY  
eFFeCTS OF TKi
Peripheral blood DCs comprising plasmacytoid and myeloid sub-
sets increase in number and function in CML patients following 
imatinib treatment (48, 106). In a murine model, DC treated with 
imatinib exhibited enhanced antigen-presenting cell function 
and restored the responsiveness of tolerant tumor-specific CD4+ 
T cells, resulting in enhanced vaccine efficacy (107). Treatment 
with imatinib, nilotinib, or dasatinib is associated with reduced 
memory B cell frequencies and significant impairment of B cell 
responses in CML (32). While a blunted antigen-specific immune 
response is observed in CML patients at diagnosis, LAA-specific 
CTL responses are readily detected in TKI-induced MMR and 
MR4.5 when the leukemic cell load is lower, suggesting effective 
restoration of anti-leukemic effector responses (12). Chen et al. 
(108) have also detected CTL responses in the majority of CML 
patients in remission on imatinib, confirming the immune sys-
tem’s ability to respond to leukemia under certain conditions. It is 
possible the restoration of LAA-CTL responses in CML patients 
on TKI is closely linked to effective inhibition of aberrant PD-1 
signaling, a potential consequence of diminishing antigenic 
stimulation in light of the significantly reduced leukemic cell load 
on TKI.
Dasatinib is unique in its ability to induce expansion of large 
granular lymphocytes (LGLs), consisting of mono- or oligo-
clonal CD8+ T cells and NK cells, shown to correlate with better 
prognosis and consequently more favorable response in patients 
with CML (109–112). Twenty-hour pretreatment of NK cells with 
dasatinib followed by washout, led to dose-dependent enhance-
ment of NK  cell cytokine production, degranulation marker 
expression, and cytotoxicity against lymphoma and leukemia 
cell lines (113). Hayashi and colleagues (114) have reported 
dasatinib treatment markedly enhances NK cell cytotoxic func-
tion in CML patients and this is associated with an increased 
number of cells in the NK lineage, including CD3−CD56+ and 
mature CD56+CD57+ cells to levels not obtained with imatinib or 
nilotinib (115). CML patients in MMR and MR4.5 on TKI display 
a more mature, cytolytic CD57+CD62L− NK  cell phenotype, 
consistent with restoration of NK  cell activating and inhibi-
tory receptor repertoire compared to their downregulation at 
diagnosis (12). Comparative analysis of NK  cell and T  cell 
receptor repertoires in patients treated with imatinib frontline or 
nilotinib and dasatinib as first- or second-line therapy has been 
performed (116). The lymphocyte count and absolute number 
of NK  cells was not significantly different between the treat-
ment groups. Phenotypic analysis of NK cell receptors revealed 
dasatinib-treated patients displayed an increased expression 
of KIR (KIR2DL1) receptors, while imatinib-treated patients 
exhibited an increased expression of activating receptors (NKp30, 
NKp46, NKp80, and NKG2D).
The immunostimulatory effects of dasatinib also extend to 
immune suppressors, as dasatinib has the potential to reduce 
Treg in both bone marrow and peripheral blood, skewing the 
balance of immune suppression toward activation and prolifera-
tion, promoting immune stimulation (115). Treg reduction has 
been shown to be markedly enhanced in dasatinib-treated CML 
patients developing LGL lymphocytosis (109, 117). Balachandran 
et al. (23) have found that the immune system contributes sub-
stantially to the antitumor effects of imatinib via the inhibition 
of indoleamine 2,3-dioxygenase (IDO), an important regula-
tory checkpoint influencing Treg expansion and activity (118). 
Imatinib activates CD8+ T cells and NK cells and leads to apoptosis 
of immunosuppressive Treg (23, 119). At clinically relevant doses, 
imatinib treatment of mice reduces Treg frequency and inhibits 
Treg suppressive activity and FoxP3 expression in vivo (120). The 
induction and persistence of Treg immunosuppressive function is 
dependent on FoxP3 (120). Zahran et al. (78) have reported Treg 
numbers are significantly lower in CML patients achieving DMR 
on imatinib therapy compared to diagnosis and patients not 
achieving DMR. Hayashi et al. (114) also revealed the frequency 
of Treg decreased in patients treated with imatinib, nilotinib, or 
dasatinib, with the percent decrease of Treg comparable among 
the three treatment groups (Figure 1).
Giallongo et al. (13) have previously shown MDSC decrease 
to normal levels in CML patients following imatinib therapy, 
and more recently, both imatinib and dasatinib have been 
shown to modulate the immunosuppressive CML tumor milieu, 
leading to decreased numbers of MDSC and associated inhibi-
tory molecule arginase-1 expression (121). The TKI sunitinib 
reduces the frequency of MDSC and reverses T  cell immune 




Several clinical trials including the landmark STIM (122, 123) 
and CML 8 (TWISTER) (5) trials have demonstrated that ~40% 
of CML patients in stable DMR successfully maintain TFR after 
stopping imatinib therapy. Importantly, all patients in molecular 
relapse (MolR) remained responsive to imatinib re-treatment, 
and most patients who relapsed did so within 6  months of 
imatinib cessation. Many other TFR stopping trials are currently 
ongoing, some with less stringent criteria for relapse than earlier 
studies, such as loss of MMR for re-starting TKI therapy and 
FiGURe 1 | immune effector recovery in CML patients achieving deep molecular response on TKi therapy. Diagnosis CP CML; suppression of the 
immune system in CP CML patients at diagnosis is mediated in part by hematopoietic stem cells, which acquire a proliferative/survival advantage and lose the ability 
to undergo apoptosis. Release of tumor-derived cytokines/chemokines drives the expansion of immune suppressor MDSC and Treg, facilitating downregulation of 
antitumor effector immunity. PD-L1 is upregulated on CML cells, where it interacts with the coinhibitory receptor PD-1, and contributes to protection of the malignant 
cells from immune destruction. MDSC originate from the malignant BCR-ABL1 clone and mediate their suppressive activity via a number of mechanisms, including 
increased production of reactive oxygen and nitrogen species (NO, ROS), arginase-1, and TGF-β1. MDSC can induce Treg expansion, and Treg also express PD-1 
to promote enhanced suppressor function. Post-TKI treatment; TKI exert immunomodulatory effects, particularly against key suppressor MDSC and Treg 
populations, conferring immune system re-activation and restoring effector-mediated immune surveillance. More specifically, TKI treatment leads to restoration of 
NK cell receptor repertoire and enhanced NK cell function, restoration of LAA-CTL responses, including downregulation of PD-1 to normal levels, and increased DC 
number and antigen-presenting cell function. CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor; CP, chronic phase; MDSCs, myeloid-derived suppressor 
cells; Treg, regulatory T cells; PD-L1, programmed death ligand-1; PD-1, programmed death-1; NO, nitric oxide; ROS, reactive oxygen species; TGF-β1, 
transforming growth factor-β1; NK, natural killer; LAA, leukemia-associated antigen; CTL, cytotoxic T lymphocyte; DC, dendritic cell.
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others evaluating discontinuation of second-generation TKIs 
(124–130). Rea and colleagues (130) provided the first report of 
cessation of second-generation TKI dasatinib or nilotinib (STOP 
2G-TKI) in CML patients, TFR rates at 12 and 48 months were 
63% (CI: 51–76%) and 55% (CI: 40–67%), respectively. Prior 
suboptimal TKI response or TKI resistance was the only base-
line patient characteristic associated with a significantly higher 
incidence of MolR following cessation. The largest discontinua-
tion study to date, the European stop TKI (EURO-SKI) trial has 
recently reported a molecular recurrence-free survival of 52% 
(CI: 48–56%) in 750 CP CML patients treated with imatinib, 
nilotinib, or dasatinib at 24 months, using loss of MMR as the 
criteria for relapse (126).
The lack of overt relapse in such patients, despite the pres-
ence of very low levels of residual disease has been attributed to 
immunological control of CML (131), challenging the long-held 
belief that SCT represents the only “curative” therapy for CML 
and indicating that complete elimination of residual CML stem 
cells is not necessary in all patients to successfully achieve TFR 
(132). DMR occurs in ~20% of imatinib treated patients in the 
first 2–3  years of therapy; however, using more potent TKIs 
dasatinib and nilotinib, the rates of DMR are faster and deeper, 
and it is possible that this will lead to more patients eligible to 
attempt TFR in a shorter time frame (133, 134). However, it is 
also likely that the optimum duration of TKI treatment before 
discontinuation attempt is heterogeneous and varies between 
patients (135). To this end, identifying predictive factors for suc-
cessful discontinuation of TKI and thus, identification of CML 
patients who would benefit most from discontinuation remains 
a key issue (6).
ROLe OF THe iMMUNe SYSTeM FOR 
SUCCeSSFUL TFR
To date, more than 2,000 CML patients worldwide have attempted 
to discontinue TKI after achieving DMR in the clinical trial set-
ting (6). More recently, several immunological sub-studies within 
larger discontinuation trials have attempted to identify immu-
nological predictive factors of TFR maintenance, typically prior 
to TKI cessation (baseline immune markers) (6). Results from 
Immunostim, performed on a subset of 51 patients enrolled in the 
STIM trial, identified an association between elevated peripheral 
blood NK cells and positive clinical outcome following imatinib 
discontinuation (136). Accordingly, these observations provided 
some of the first evidence that NK cell based immune surveillance 
may contribute to CML control following TKI cessation. More 
recent molecular data (A-STIM and EURO-SKI trials) demon-
strating fluctuating BCR-ABL1 levels just below MMR without 
loss of MMR, and therefore without TKI resumption, has all but 
confirmed the importance of the role of immune surveillance for 
sustained TFR in CML. Immunostim did not observe any asso-
ciation between CD3+/CD4+/CD8+ T cells, the CD4/CD8 ratio, 
or Treg numbers in patients who relapsed compared to those who 
did not. Patient characteristics revealed 52.9% of the patients had 
received prior IFN therapy, shown in other studies to contribute 
to higher TFR rates (5, 137). Induction of a PR3-specific CTL 
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response by IFN has been shown to contribute to this effect (138). 
Prior to the advent of TKI therapy, patients treated with IFN 
who discontinued treatment without relapse showed increased 
NK  cell counts (139). IFN/imatinib induction treatment fol-
lowed by a temporary IFN maintenance may enable a higher rate 
of treatment discontinuation in CML patients in at least MMR 
when stopping TKI (140). The TIGER study (NCT01657604) is 
currently investigating de-escalating maintenance therapy using 
low dose IFN as an inducer of immune surveillance following 
nilotinib discontinuation.
In keeping with the NK  cell effector responses observed in 
Immunostim, a subgroup analysis of 45 patients in the EURO-
SKI clinical trial has also shown that patients with higher NK cell 
counts at the time of TKI discontinuation are more likely to have 
successful TFR, linked to an increased frequency of more mature 
(CD57+) and cytotoxic (CD16+ and CD57+) NK cells (18). Prior 
IFN treatment showed no statistically significant correlation 
between relative or absolute numbers of NK cells. Similar associa-
tion to successful TFR was not found with T cells or B cells or 
their subsets. The low affinity Fcγ receptor III (CD16) facilitates 
antibody-dependent cellular cytotoxicity, involved in triggering 
NK  cell cytotoxicity (141). However, evaluation of activating 
NK cell surface receptors: NKG2C, NKp46, and NKG2D, which 
control NK cell cytotoxic responses revealed no significant differ-
ence between the patient groups. We have examined expression 
levels of all three natural cytotoxicity receptors NKp30, NKp44, 
and NKp46 and additional C-type lectin receptors NKG2A, 
NKG2C, NKG2D, CD161, and CD69 in Australian CML patients 
at time of TKI cessation and 3 and 6 months after (142). NKG2D 
represented the only differentially expressed receptor, decreased 
in MolR patients when compared to TFR at all three time points 
assessed. The functional degranulation response of CD3−CD56dim 
NK cells following target cell stimulation does not appear to be 
different between TFR and MolR (18, 136, 142). In further analysis 
by EURO-SKI, TFR patients had more NK cells that had down-
regulated CD16 (CD16−) upon K562 stimulation, suggesting an 
increased activity of these cells. In addition, the TNF-α/IFN-γ 
cytokine secretion by these activated CD56dimCD16− NK  cells 
correlated with TFR success (18). A separate sub-study of 122 
EURO-SKI patients has recently reported that increased CD86+ 
pDCs, which mediate immune tolerance are found in MolR 
patients at the time of TKI cessation, and thus low CD86+ pDC 
might be predictive of TFR (19). This study also found that higher 
numbers of pDCs correlated with increased PD-1-expression 
on PR3-specific CD8+ CTLs, suggesting immune exhaustion 
contributes to relapse risk.
The specific role and/or predictive ability of NK cells in suc-
cessful dasatinib cessation is currently unclear. In the Japanese 
D-STOP trial, patients with DMR on TKI received dasatinib 
consolidation therapy for 2 years prior to cessation, and at the 
end of the consolidation period, there was a significant increase in 
the proportion of CD3−CD56+ NK cells in patients who relapsed 
(127). In contradistinction, the Japanese DADI trial (125) where 
patients received dasatinib consolidation for 1 year prior to ces-
sation showed high NK  cell (CD3−CD56+ and CD16+/CD56+) 
and NK cell LGL (CD56+CD57+) numbers, and low γδ T cells 
and Treg (CD25+CD127low) counts prior to stopping second line 
dasatinib treatment were associated with an increased likelihood 
of TFR success. Treg facilitate tumor cell immune evasion and 
may be a contributing factor responsible for relapse in these 
patients. By contrast, other studies have reported no difference in 
Treg or Treg naïve/memory subsets in TFR patients compared to 
those who relapsed (136, 142). This difference may reflect hetero-
geneity of distinct immune subsets, which are pre-conditioned by 
different TKI treatment modalities prior to cessation attempt. For 
example, DADI requires 1 year of dasatinib consolidation therapy 
prior to cessation, while Immunostim and our recently reported 
Australian data represent a predominantly imatinib treated 
patient cohort. Yoshida et al. (143) have suggested a critical role of 
Treg inhibition by dasatinib for the induction of NK cell effector 
differentiation and achievement of DMR and dasatinib has been 
previously shown to potently inhibit the proliferation and func-
tion of CD4+CD25+ Treg (24). Thus, it is possible the enhanced 
NK cell immune effector phenotype observed in patients who did 
not relapse in DADI, acting in concert with reduced immune sup-
pressive Treg, reduces the likelihood of relapse in CML patients 
following TKI discontinuation. Further studies are needed to 
ascertain the mechanisms responsible for achievement of TFR 
in the absence of reduced Treg as it does not appear that reduced 
Treg numbers are critical in all TFR scenarios.
The only difference in immune suppressors observed in our 
Australian patient cohort was increased monocytic MDSC in 
MolR patients at the time of TKI discontinuation. It is possible 
monocytic MDSC, which play an important role in suppression 
of host immune responses, including effector NK responses 
(144) block or dampen immune surveillance, a necessary 
component against relapse in CML. Therapeutic strategies 
aimed at targeting the number and/or function of MDSC, 
such as promoting their differentiation into mature myeloid 
cells that do not have suppressive abilities, inhibition of the 
signaling pathways that regulate MDSC suppressive factors, 
or elimination of MDSC using chemotherapeutic drugs may 
further enhance TFR success rates (62). We have also identified 
reduced KIR2DL2/DL3/DS2 positive NK cells in TFR patients 
at 3  months and 6  months post-TKI cessation compared to 
MolR patients (142). In this setting, it is possible antibodies 
that block KIR on NK  cells may enhance TFR success rates. 
However, inhibition of KIR2D with the monoclonal antibody 
IPH2101 has been shown recently to induce contraction and 
hyporesponsiveness of NK cells in patients with myeloma, with 
reductions in NK function directly correlating with loss of free 
KIR2D surface molecules (145). This finding may compromise 
antibody-based strategies designed at augmenting NK  cell 
tumor killing via KIR inhibition in CML.
Killer immunoglobulin-like receptor genotypes have been 
reported to influence the probability of achieving molecular 
response in CML; however, none has yet emerged as a reliable 
predictor of TFR after DMR has been achieved (135). Caocci et al. 
(146) reported KIR polymorphisms that could be significantly 
associated with increased likelihood of TFR success. Interestingly, 
one of the haplotypes has already been reported to be significantly 
linked to the TKI response (KIR2DL5B) (147). However, there 
was no difference observed in KIR genotypes in EURO-SKI 
patients with TFR success compared with MolR (18).
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CONCLUDiNG ReMARKS AND FUTURe 
DiReCTiONS
Treatment-free remission attempts are safe and are feasible in 
most well-responding CP CML patients, and the impact of imple-
menting stopping strategies as a routine part of clinical practice 
in CML would be significant, from both a patient-centered and 
medico-economic viewpoint. At present, available data show that 
MolR typically occurs within 6 months of TKI discontinuation, 
and most studies have identified the majority of clinical prognostic 
factors in patients prior to stopping TKI. Normalization of many 
immune cell populations early in the setting of TFR and MolR, at 
least by 3 months following the initial timepoint of TKI cessation, 
may be linked to the dynamic nature of the immune system as 
evidenced by its constant immune surveillance and the enhanced 
net effector immune responses and decreased PD-1 and immune 
suppressors observed in CML patients in DMR compared to 
diagnosis (12). Thus, longer follow-up of patients in all TFR 
studies is critically needed to determine how long patients will 
ultimately be able to maintain TFR (148). In this regard, immune 
monitoring may reveal an optimum threshold level of immune 
effector responses in which TKI cessation is more achievable and 
successful, which could prove especially informative for patients 
contemplating a second TKI discontinuation attempt following 
initial failure. Preliminary data suggest a net balance between 
both the effector and suppressor arms of the immune system may 
be important in mediating TFR success (142); however, a major 
goal remains to identify the most effective pathways to target to 
maximize an advantageous immune response and promote TFR 
success. Based on what is known regarding NK cell frequency in 
TFR, trials are underway using pharmacological manipulation, 
such as lenalidomide, which stimulates NK cells and enhances 
antitumor responses, in combination with TKI to further aug-
ment TFR success in CML (ACTRN12615001169538), or using 
IFN in combination with a second-generation TKI such as 
nilotinib (NCT02001818) to enhance immune-modulation prior 
to a TFR attempt. In conclusion, the identification of a robust 
immunological biomarker that accurately predicts which patient 
may stop TKI without relapse, and delineation of the precise 
mechanisms involved in TFR success should become a primary 
goal of future discontinuation studies in CML.
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